Glycemic Management

Adolescents and young adults with type 1 diabetes had lower glucose levels on days when they reported feeling more engaged with their diabetes management, according to findings published in Diabetic Medicine.

Adults with type 2 diabetes had lower fasting glucose and increased time in range with a time-restricted eating window of 10 hours compared with an eating window of 14 hours or longer, according to study data.

Older adults with type 1 diabetes using hybrid closed-loop insulin pump therapy had more time in range during sleep, but worse sleep quality compared with those using sensor-augmented therapy, according to study findings.

Use of continuous glucose monitoring for glycemic management and inpatient diabetes education before discharge may improve outcomes for hospitalized adults with diabetes at risk for hyperglycemia, according to clinical practice guidelines.

The FDA has lifted a clinical hold placed on a trial for an investigational stem cell-derived therapy for people with type 1 diabetes, according to an industry press release.

A small cohort of pregnant women with type 1 diabetes improved time in range with use of a closed-loop insulin delivery system with a zone model predictive control algorithm, according to findings from a small pilot study.

Adults with type 2 diabetes who drank a low-dose premeal shot of whey protein before each meal spent less time in hyperglycemia and more time in range compared with placebo, according to study findings.

Older adults with type 1 diabetes initiating continuous glucose monitoring for the first time had a reduction in time spent in hypoglycemia, improved time in range and a lower HbA1c, according to findings from a randomized clinical trial.

NEW ORLEANS — Adults and children with type 1 diabetes who used an open-source automated insulin delivery system significantly increased time in target glucose range compared with baseline and with sensor-augmented pump therapy.

NEW ORLEANS — There is no single answer when it comes to determining the primary target for treating type 2 diabetes, two speakers said during a debate at the American Diabetes Association Scientific Sessions.